{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:59:39Z","timestamp":1778914779244,"version":"3.51.4"},"reference-count":183,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"unspecified","delay-in-days":117,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias","award":["PI14\/0700"],"award-info":[{"award-number":["PI14\/0700"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["PI14\/0063"],"award-info":[{"award-number":["PI14\/0063"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["PI016\/0503"],"award-info":[{"award-number":["PI016\/0503"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["PI17\/0420"],"award-info":[{"award-number":["PI17\/0420"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["PI17\/0498 and PI19\/01337"],"award-info":[{"award-number":["PI17\/0498 and PI19\/01337"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["COVID19 617"],"award-info":[{"award-number":["COVID19 617"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut and BIOCET, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["INT19\/00036 and INT20\/00031"],"award-info":[{"award-number":["INT19\/00036 and INT20\/00031"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2021,6,13]]},"DOI":"10.1080\/14656566.2021.1887140","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T11:29:44Z","timestamp":1614338984000},"page":"1127-1141","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)"],"prefix":"10.1080","volume":"22","author":[{"given":"Mar\u00eda Del Mar","family":"Gutierrez","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit. Hospital De La Santa Creu I Sant Pau, Institut De Recerca Del Hospital De La Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-8483","authenticated-orcid":false,"given":"Isabel","family":"Mur","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit. Hospital De La Santa Creu I Sant Pau, Institut De Recerca Del Hospital De La Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Gracia","family":"Mateo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit. Hospital De La Santa Creu I Sant Pau, Institut De Recerca Del Hospital De La Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-6186","authenticated-orcid":false,"given":"Francesc","family":"Vidal","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit. Hospital Universitari Joan XXIII, Universitat Rovira I Virgili, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5770","authenticated-orcid":false,"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit. Hospital De La Santa Creu I Sant Pau, Institut De Recerca Del Hospital De La Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"cit0001","unstructured":"COVID-19 Map. Johns Hopkins University. Baltimore, Maryland: coronavirus resource center. 2020. Available at [last accessed 2020 Sept 7]. https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102887"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa576"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.006"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1051-9"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.003"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248"},{"key":"cit0012","unstructured":"Corticosteroids for COVID-19. Living Guidance. World Health Organization. 2020 Sept 2. Available at: [last accessed 2020 Nov 30]. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-corticosteroids-2020.1"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"issue":"18","key":"cit0014","first-page":"1775","volume":"323","author":"Onder G","year":"2020","journal-title":"JAMA"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1966"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000947"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050639"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.026"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002555"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058812"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.3201\/eid1911.130546"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318246b862"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001712"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1002\/path.2276"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00056-0"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir627"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-008-9449-2"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25732"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa408"},{"key":"cit0031","doi-asserted-by":"crossref","unstructured":"Guo W, Ming F, Dong Y. A survey for COVID-19 among HIV\/AIDS patients in two districts of Wuhan, China. 2020. Available at SSRN: (preprint). [Last accessed 2020 May 5]. https:\/\/ssrn.com\/abstract=3550029","DOI":"10.2139\/ssrn.3550029"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30111-9"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30164-8"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3689"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104826"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa579"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01438-z"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa657"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25955"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002423"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa635"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa880"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2020.0103"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26077"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26029"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.11.20151688"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.07.20170449"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.07.20169490"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.02.20145185"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30140-5"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25881doi:10.1002\/jmv.25881"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001235"},{"key":"cit0053","unstructured":"Identifier NCT04379245, COVID-19 Infection in Patients Infected With HIV and\/or on PrEP (COVIDHIVPrEP). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2020 May 7. Available at: [last accessed 2020 Aug 30]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04379245"},{"key":"cit0054","unstructured":"BHIVA, DAIG, EACS, GESIDA & Polish Scientific AIDS Society Statement on risk of COVID-19 for people living with HIV (PLWH). 2020 Aug 5. Available at: [last accessed 2020 Aug 31]. https:\/\/www.eacsociety.org\/home\/bhiva-daig-eacs-gesida-and-polish-scientific-aids-society-statement-on-risk-of-covid-19-for-people-living-with-hiv-plwh.html"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01196"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25681"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25729"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104786"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104898"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.19.20038984"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00799-2020"},{"key":"cit0065","unstructured":"Horby P, Landray M. No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY. 2020 Jun 29. Available at: [last accessed 2020 Aug 10]. https:\/\/www.recoverytrial.net\/news\/no-clinical-benefit-from-use-oflopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery"},{"key":"cit0066","unstructured":"WHO discontinues hydroxychloroquine and lopinavir\/ritonavir treatment arms for COVID-19. World Health Organization. 2020. Available at: [last accessed 2020 Aug 10]. https:\/\/www.who.int\/news-room\/detail\/04-07-2020-who-discontinues-hydroxychloroquine-andlopinavir-ritonavir-treatment-arms-for-covid-19"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.05.085"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa241"},{"key":"cit0069","unstructured":"Identifier NCT04425382, Darunavir\/Cobicistat vs. Lopinavir\/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2020 Jun 11. Available at: [last accessed 2020 Aug 30]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04425382"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117592"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.03.022939"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01114-20"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.22.165712"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182185276"},{"key":"cit0075","unstructured":"Identifier NCT04334928, Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS). ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US), 2020 Aug 25. Available at: [last accessed 2020 Aug 30]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334928"},{"key":"cit0076","unstructured":"Identifier NCT04519125, Daily Regimen of Tenofovir\/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia. ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US), 2020 Aug 19. Available at: [last accessed 2020 Aug 30]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04519125"},{"key":"cit0077","unstructured":"Identifier NCT04405271, TAF\/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study). ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US), 2020 Jul 28. Available at: [last accessed 2020 Aug 30]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405271"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa455"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20201256"},{"key":"cit0080","unstructured":"Identifier NCT04441385, Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). (MARACOVID). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2020 Jul 9. Available at: [last accessed oncited 2020 Aug 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04441385"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101300"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.24.3222"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa350"},{"key":"cit0084","first-page":"85:106688","author":"Dastan F","journal-title":"Int Immunopharmacol"},{"key":"cit0085","doi-asserted-by":"crossref","unstructured":"Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon-1a in treatment of severe COVID-19. Antimicrob Agents Chem. 2020;64(9):e01061-20.","DOI":"10.1128\/AAC.01061-20"},{"key":"cit0086","first-page":"11","author":"Zhou Q","journal-title":"Front Immunol"},{"key":"cit0087","unstructured":"U.S National Library of Medicine. ClinicalTrials.gov. [cited 2020 Sep 15]. Available from: www.clinicaltrials.gov"},{"key":"cit0088","volume-title":"Type III interferons: balancing tissue tolerance and resistance to pathogen invasion","volume":"217","author":"Broggi A","year":"2020"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.013788"},{"key":"cit0090","unstructured":"Liverpool HIV Interactions. [cited 2020 Sept 12]. Available from: www.hiv-druginteractions.org"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1038\/srep43395"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.15.043166"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13940-6"},{"key":"cit0095","unstructured":"https:\/\/www.ema.europa.eu\/en\/news\/first-covid-19-treatment-recommended-euauthorisation."},{"key":"cit0096","unstructured":"https:\/\/www.covid19treatmentguidelines.nih.gov\/antiviral-therapy\/remdesivir\/."},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"cit0099","unstructured":"https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/7\/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19."},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301"},{"key":"cit0105","volume-title":"Remdesivir (GS-5734) investigator\u2019s brochure version 5.0","author":"Gilead Sciences"},{"key":"cit0106","unstructured":"The European Medicines Agency - EMA. Veklury (remdesivir). 2020."},{"key":"cit0107","unstructured":"Drug Interactions Checker - For Drugs, Food & Alcohol. Accessed: 2020 Sept 15. https:\/\/www.drugs.com\/drug_interactions.html"},{"key":"cit0108","unstructured":"Food and Drug Administration. Remdesivir by Gilead Sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment. 2020. Available at: Accessed 2020 Jul 2. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/remdesivir-gilead-sciences-fda-warns-newly-discovered-potential-drug-interaction-may-reduce"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-69"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-019-0204-x"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00302"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104228"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003833"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048238"},{"issue":"23","key":"cit0116","first-page":"e143174","volume":"5","author":"Rosenke K","year":"2020","journal-title":"Insight"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2558-4"},{"key":"cit0118","doi-asserted-by":"crossref","unstructured":"Kaptein S, Jacobs S, Langendries L. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2\u2212infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955\u201326965.","DOI":"10.1073\/pnas.2014441117"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2575-3"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.15.20151852"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019014"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4207"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1009"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012410"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8630"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003252"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.06.099"},{"issue":"20","key":"cit0129","first-page":"0","volume":"1201","author":"Dauby N","journal-title":"Int J Infect Dis"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.09.1460"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02505-x"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106144"},{"issue":"20","key":"cit0133","first-page":"30335","volume":"0953","author":"COVID-19 RISK and Treatments (CORIST) Collaboration","journal-title":"Eur J Intern Med"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m606"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0331-4"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30343-X"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103026"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.782"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"cit0142","unstructured":"Actemra (Tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; 2019.20."},{"key":"cit0143","unstructured":"Kevzara (Sarilumab) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2018.21."},{"key":"cit0144","unstructured":"Sylvant (Siltuximab) [prescribing information]. Hemel Hempstead, Hertfordshire, United Kingdom: EUSA Pharma (UK); 2019."},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8050695"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.05.001"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102568"},{"key":"cit0148","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Sanz J, Muriel A, Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicenter cohort study. Clin Microbiol Infect [Internet]. Available from: 2020 Sep. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20305735.","DOI":"10.1101\/2020.06.08.20125245"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6820"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6615"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218122"},{"key":"cit0153","doi-asserted-by":"crossref","unstructured":"Gritti G, Raimondi F, Ripamonti D, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. MedRxiv. 2020 April 01;https:\/\/doi.org\/10.1101\/2020.04.01.20048561","DOI":"10.1101\/2020.04.01.20048561"},{"key":"cit0154","unstructured":"Evidence-Based Clinical Decision Support at the Point of Care | UpToDate. Accessed: 2020 Sept 15. www.uptodate.com"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.35"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.015511"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa219"},{"key":"cit0158","doi-asserted-by":"crossref","unstructured":"Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81:318\u2013356.","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.019"},{"key":"cit0160","unstructured":"U.S National Library of Medicine ClinicalTrials.gov. Accessed 2020 Sep 15. www.clinicaltrials.gov."},{"key":"cit0161","unstructured":"Kineret (Anakinra) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; 2018."},{"key":"cit0162","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30127-2"},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.94"},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"issue":"3","key":"cit0165","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"Charles P","year":"1999","journal-title":"J Immunol"},{"key":"cit0166","unstructured":"A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). Identifier: NCT04344249. Available: Accessed: 2020 Sept 15. Clinicaltrials.gov"},{"issue":"2","key":"cit0167","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","volume":"38","author":"Sarzi-Puttini P","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"cit0168","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.062"},{"key":"cit0169","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.06.054"},{"key":"cit0170","unstructured":"Dexamethasone in Hospitalized Patients with Covid-19 \u2014 Preliminary Report. N Engl J Med [internet]. NEJMoa2021436. Available from: 2020 Jul 17. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2021436."},{"key":"cit0171","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Jac S, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA [Internet]. Available from: 2020 Sep 2. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32876694."},{"key":"cit0172","unstructured":"Tybost\u00ae (cobicistat) Highlights of prescribing information, Gilead Sciences, Inc, Aug 2020."},{"key":"cit0173","unstructured":"Norvir\u00ae (ritonavir), Highlights of prescribing information, Jun 2017."},{"key":"cit0174","unstructured":"Prezista\u00ae (darunavir), Highlights of prescribing information, Janssen-Cilag Ltd, May 2019."},{"key":"cit0175","unstructured":"Edurant\u00ae (rilpivirine), Highlights of prescribing information, Janssen-Cilag Ltd, Jan 2019."},{"key":"cit0176","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006000"},{"key":"cit0177","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06062-x"},{"key":"cit0178","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14768"},{"key":"cit0179","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.047430"},{"key":"cit0180","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14817"},{"key":"cit0181","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02105-822"},{"key":"cit0182","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02242-0"},{"key":"cit0183","first-page":"7:557","author":"Benito N","journal-title":"Front Med"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2021.1887140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T02:12:41Z","timestamp":1697940761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2021.1887140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":183,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,6,13]]}},"alternative-id":["10.1080\/14656566.2021.1887140"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2021.1887140","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}